
ECigIntelligence: MEPs Lack Knowledge on New Nicotine Products, Survey Shows
Members of the European Parliament are less aware of key issues surrounding new nicotine products than in previous years, despite being asked to vote on important new legislation concerning the topic in the coming months, according to a new survey.
But the third annual survey, conducted by business intelligence researcher Tamarind Intelligence, publisher of leading intelligence platforms ECigIntelligence and TobaccoIntelligence, shows that the more MEPs know about new nicotine products (e-cigarettes, nicotine pouches and heated tobacco), the more likely they are to consider that these products are less harmful than cigarettes.
Among its key findings, the report shows that:
- MEPs rarely believe that new nicotine products are as harmful as smoking – only 19% of responses, the lowest number since the annual survey was launched in 2020 – and a majority believe they are less harmful than smoking.
- MEPs with no knowledge of new nicotine products are becoming far more likely to acknowledge that they don’t know the risks. In previous years MEPs were quick to adopt a position in one direction or the other, but in 2022 half of MEPs with no knowledge said they didn’t know the risks of these products.
- MEPs with some knowledge of new nicotine products strongly tend to believe (76% of responses) that they are less harmful than smoking.
- While very few MEPs consider that new nicotine products should be more restricted than traditional tobacco, and a majority believe online sales should be allowed for adults (with age verification), more MEPs are unsure how they should be regulated than in previous years.
Tim Phillips, Managing Director of Tamarind Intelligence, said:
“Our 3rd annual MEP Survey results are particularly relevant given the recent launch of the European Commission’s public consultation on evaluating the legislative framework for tobacco control at the end of February 2023, and the adoption by the European Parliament of the BECA committee’s recommendations over a year ago. As some of the questions in the Commission’s consultation are similar to the ones we asked in our MEP Survey, it will be fascinating to see if MEPs views on the topic of new nicotine products will be in line with responses to the public consultation.”
Further information and data from the survey is included in this document.
The survey was carried out online and anonymously, and all data from it remains confidential other than as used in consolidated analysis. The survey was sent to all MEPs (from all member states and political parties) and responses were obtained from 43 MEPs representing 6% of the European Parliament.
ENDS
About Tamarind Intelligence:
Tamarind Intelligence is publisher of ECigIntelligence and TobaccoIntelligence, the leading providers of detailed global market and regulatory data for the e-cigarette and vaping sectors and heated tobacco/nicotine pouch markets worldwide. Tamarind is an independent business intelligence service providing objective market and regulatory data to industry participants, related industry players, governments and Non-Governmental Organisations worldwide from its headquarters in London and Barcelona.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230301005866/en/
Contact information
Carmen de Capua
Contact: marketing@tamarindintelligence.com
About Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Alveo Technologies Announces ISO 13485:2016 Certification21.3.2023 14:45:00 CET | Press release
Alveo Technologies, Inc. (Alveo), a leader in molecular sensing and diagnostics with its proprietary be.well™ technology platform, today announced its quality management system (QMS) has achieved ISO 13485:2016 certification for the design, development and manufacture of in vitro diagnostic kits and analyzers for the detection of infectious disease. The globally recognized ISO 13485 standard, published by the International Standards Organization, sets out requirements for establishing and maintaining quality management systems for the medical device industry. Compliance with the ISO 13485 standard is required for companies to market medical devices in many markets, including the European Union, Canada, Japan, and Australia. In addition, the U.S. Food and Drug Administration has announced plans to harmonize its existing medical device QMS requirements with ISO 13485, proposing new regulations that incorporate ISO 13485 as the foundational requirements. “We are thrilled to achieve ISO 13
Wemade Presents ‘ Wateree’s Enhancement Support Event’ to Boost Growth in MIR M21.3.2023 14:00:00 CET | Press release
Wemade's blockbuster MMORPG MIR M: Vanguard and Vagabond (hereinafter "MIR M") is holding the "Wateree’s Enhancement Support" event starting from March 21st, 2023. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230321005487/en/ ‘Wateree’s Enhancement Support Event’ for MIR M starts on March 21, 2023 (Graphic: Wemade) For two weeks, users can participate in two attendance events called "Wateree's Enhancement Support 7 Days Check-in," and "Wateree's Illusory Mystic Realm Support 7 Days Check-in." Simply by checking in, users can obtain abundant rewards such as "Enhancement Stone," "Reforging Stone," "Oil of Blessing," "Illusory Mystic Realm Entry Ticket," and the EXP buff item, "Growth Draught," and more, depending on the number of attendances in the Check-in events. There are also special items available in the in-game Shop for improving crafting and enhancement mastery. The "Wateree's Crafting Mastery Support" package, which
MIR4 Updates ‘Sabuk Clash’ to Determine the Most Powerful Clan21.3.2023 14:00:00 CET | Press release
Wemade’s blockbuster MMORPG MIR4 updated Sabuk Clash, clan vs. clan Castle Siege, on March 21st. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230321005465/en/ MIR4 Updates ‘Sabuk Clash,’ a tournament style Castle Siege content to determine the Emperor’s Clan, on March 21 (Graphic: Wemade) “Sabuk Clash” is a tournament style Castle Siege content where King’s clans from all servers in each region gather in the Domination Server and fight to become the Emperor’s clan. Only Bicheon Castle King’s clans can participate. The winning clan then becomes the Emperor’s clan, which can collect taxes from the Kings of all servers in each region, adjust individual tax rates per server, and is given authority to manage the Sabuk Castle territory. The first round begins on March 26th at 10 pm, and a new round will be held every week for a total of 3 rounds over 3 weeks. In the first round, a total of 16 clans fight to capture one of the 8
Viz.ai is First to Receive FDA 510(k) Clearance for AI Algorithm for Abdominal Aortic Aneurysm21.3.2023 13:02:00 CET | Press release
Viz.ai, the leader in AI-powered disease detection and intelligent care coordination, today announced it has received U.S. Food and Drug Administration (FDA) 510(k) clearance for its algorithm intended to detect suspected abdominal aortic aneurysm (AAA). Viz AAA is the first FDA-cleared AI-powered solution for the detection and triage of suspected AAA. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230321005445/en/ Viz AAA is the first FDA-cleared AI-powered solution for the detection and triage of suspected AAA. (Photo: Business Wire) “There is an estimated 1.1 million Americans living with an AAA1. Majority of these patients are asymptomatic and many are unaware of their disease until a rupture occurs. This is a catastrophic medical emergency, resulting in over 10,000 deaths each year,” said Philip Batista, MD, Associate Program Director, Vascular and Endovascular Surgery Residency, Cooper. “This algorithm is a powerful ne
José Baselga Research Fund Announces First-Ever Grant to Advance Prion Disease Research21.3.2023 13:02:00 CET | Press release
The José Baselga Research Fund (JBRF), supported by Alexion, AstraZeneca Rare Disease, today announced the initiation of the Global José Baselga Research Grant (Baselga Grant), an annual $75,000 grant to advance the treatment of prion diseases, a group of rare progressive neurodegenerative disorders. JBRF was created by the Baselga family in memory of Dr. José Baselga, a physician-scientist who dedicated his life to the advancement of cancer therapy before passing away two years ago today from Creutzfeldt-Jakob Disease (CJD), an extremely rare, fatal neurodegenerative condition. The Baselga Grant will honor Jose’s legacy and support scientists in the pursuit of understanding, and eradicating, prion diseases such as CJD. “Our family feels incredibly lucky to have had such an amazing father and husband for as long as we did, and we are committed to continuing his legacy of improving people’s lives through innovative medicines,” commented Clara Baselga-Garriga, daughter of José and studen